Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001
Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High Following Analyst Upgrade
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High After Better-Than-Expected Earnings
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics: A Potential Future Psoriasis Play
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy?
Oruka Therapeutics Announces New Board Member and Board Transition
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics Announces $180 Million Private Placement
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics to Present at Multiple March Investor Conferences
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress